智飞生物 (300122.SZ) Latest Company News

Sep 4, 2026, 07:54 UTC
Zhifei Biological's subsidiary Chongqing Chen'an Biotech officially launched its liraglutide injection (Dashuchen) into the market with a shipment ceremony on September 4, 2026.
Source:
- finance.sina.cn
Sep 1, 2026, 08:53 UTC
Zhifei Biological's subsidiary Anhui Zhifei Longcom Biopharmaceutical received acceptance from China's National Medical Products Administration for its clinical trial application of a freeze-dried human rabies vaccine (ZFB-3 cells), allowing trials to proceed within 60 days if no objections are raised.
Source:
- finance.sina.cn
Aug 28, 2026, 11:11 UTC
Zhifei Biological reported a net loss of 809 million yuan for the first half of 2026, compared with a loss of 606 million yuan in the same period of 2025.
Source:
- finance.sina.cn
Aug 13, 2026, 01:57 UTC
Zhifei Biological's controlled subsidiary Chen'an Bio completed first-subject enrollment in the Phase Ib clinical trial of its CA111 injection on August 12, 2026.
Source:
- finance.sina.cn
Aug 10, 2026, 10:31 UTC
Zhifei Biological's wholly-owned subsidiary Zhifei Luzhu's clinical trial application for a nasal spray recombinant respiratory syncytial virus vaccine was accepted by the National Medical Products Administration, with acceptance number CXSL2600844.
Source:
- finance.sina.cn
Jul 20, 2026, 10:39 UTC
Zhifei Biological plans to repurchase its own shares for 150 million to 300 million yuan at a price not exceeding 18.22 yuan per share.
Source:
- finance.sina.cn
Jul 10, 2026, 10:30 UTC
Zhifei Biological's controlled subsidiary Chongqing Chen'an Biopharmaceutical Co., Ltd. received a Drug Registration Certificate from the National Medical Products Administration for its liraglutide injection.
Source:
- finance.sina.cn

300122.SZ

Zhifei Biological's subsidiary Chongqing Chen'an Biotech officially launched its liraglutide injection (Dashuchen) into the market with a shipment ceremony on September 4, 2026.

Zhifei Biological reported a net loss of 809 million yuan for the first half of 2026, compared with a loss of 606 million yuan in the same period of 2025.

Zhifei Biological's controlled subsidiary Chen'an Bio completed first-subject enrollment in the Phase Ib clinical trial of its CA111 injection on August 12, 2026.

Zhifei Biological's wholly-owned subsidiary Zhifei Luzhu's clinical trial application for a nasal spray recombinant respiratory syncytial virus vaccine was accepted by the National Medical Products Administration, with acceptance number CXSL2600844.

Zhifei Biological plans to repurchase its own shares for 150 million to 300 million yuan at a price not exceeding 18.22 yuan per share.

Zhifei Biological's controlled subsidiary Chongqing Chen'an Biopharmaceutical Co., Ltd. received a Drug Registration Certificate from the National Medical Products Administration for its liraglutide injection.